Friday, 16 June 2017

The Klein Law Firm Announces a Class Action Filed on Behalf of Puma Biotechnology, Inc. Shareholders and a Lead Plaintiff Deadline of July 7, 2017

NEW YORK--(BUSINESS WIRE)--The Klein Law Firm announces that a class action complaint has been

filed on behalf of shareholders of Puma Biotechnology, Inc. (NASDAQ:

PBYI) who purchased shares between February 29,

2016 and May 4, 2017. The action,

which was Best Attorney College Station filed in the United States District Court for the Best Attorney Central

District of California, alleges that the Company violated federal

securities laws.

In particular, the complaint alleges that throughout the Class Period,

defendants made materially false and/or misleading statements and/or

failed to disclose that (i) the Company did not anticipate that the U.S.

Food and Drug Administration ("FDA") would ultimately approve PB272 < br>
("neratinib") for the treatment of breast cancer; (ii) as such, Puma

Biotechnology had overstated the drug's approval prospects and/or

commercial viability; and (iii) as a result, Puma Biotechnology's public

statements were materially false and misleading at all relevant times.

Shareholders have until July 7, 2017 to petition the court for

lead plaintiff status. Your ability to share in any recovery does not

require that you serve as lead plaintiff. You may choose to be an absent

class member.

If you suffered a loss during the class period and wish to obtain

additional information, please contact Joseph Klein, Esq. by telephone

at 212-616-4899 or visit

Joseph Klein, Esq. is an experienced attorney and has also practiced as

a Certified Public Accountant. Mr. Klein represents investors and

participates in securities litigations involving financial fraud

throughout the nation. Attorney advertising. Prior results do not

guarantee similar outcomes.

No comments:

Post a Comment